Skip to main content
Top
Published in: Acta Diabetologica 2/2009

01-06-2009 | Original Article

Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels

Authors: Masafumi Koga, Hiroshi Saito, Mikio Mukai, Michio Otsuki, Soji Kasayama

Published in: Acta Diabetologica | Issue 2/2009

Login to get access

Abstract

Serum glycated albumin (GA) is the clinical markers reflecting recent plasma glucose levels. We have previously clarified that serum GA levels are low for obesity and chronic inflammation is involved in the obesity-associated decrease in GA levels through acceleration of albumin catabolism. The present study investigated whether smoking, which is a representative factor that increases CRP, affects serum GA levels. One hundred and three male subjects with normal glucose tolerance (70 nonsmokers, 33 smokers) were enrolled in this study. Smokers and nonsmokers displayed no significant differences in fasting plasma glucose (FPG), oral glucose tolerance test 2-h glucose and HbA1C. CRP levels were significantly higher in smokers than in nonsmokers (P < 0.05). Serum GA levels were significantly lower in smokers than in nonsmokers (P < 0.05). Stepwise multivariate regression analysis identified FPG and age as positively associated, and BMI and smoking as negatively associated with serum GA levels. In conclusion, serum GA levels were significantly lower in smokers than in nonsmokers. Smoking was identified as a significant negative explanatory variable for serum GA levels. These findings suggest that the inflammation-induced acceleration of albumin metabolism may be involved in the mechanism by which smoking is associated with serum GA levels.
Literature
1.
go back to reference Cohen MP (1998) Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy? J Diabet Complications 2:214–217 Cohen MP (1998) Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy? J Diabet Complications 2:214–217
2.
go back to reference Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A (1976) Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med 295:417–420PubMed Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A (1976) Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med 295:417–420PubMed
3.
go back to reference Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 20:21–27CrossRef Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 20:21–27CrossRef
4.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
5.
go back to reference Jeffcoate SL (2004) Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 21:657–665PubMedCrossRef Jeffcoate SL (2004) Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 21:657–665PubMedCrossRef
6.
go back to reference Bry L, Chen PC, Sacks DB (2001) Effects of haemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 47:153–163PubMed Bry L, Chen PC, Sacks DB (2001) Effects of haemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 47:153–163PubMed
7.
go back to reference Paroni R, Ceriotti F, Galanello R, Battista LG, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, Lapolla A, Mosca A (2007) Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 40:1398–1405PubMedCrossRef Paroni R, Ceriotti F, Galanello R, Battista LG, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, Lapolla A, Mosca A (2007) Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 40:1398–1405PubMedCrossRef
8.
go back to reference Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes JW (1979) Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci USA 76:4258–4261PubMedCrossRef Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes JW (1979) Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci USA 76:4258–4261PubMedCrossRef
9.
go back to reference Takei I (2003) Glycoalbumin. Lab Clin Pract 21:80–84 (Japanese) Takei I (2003) Glycoalbumin. Lab Clin Pract 21:80–84 (Japanese)
10.
go back to reference Nishimura R, Kanda A, Sano H, Matsudaira T, Miyashita Y, Morimoto A, Shirasawa T, Kawaguchi T, Tajima N (2006) Glycated albumin is low in obese, non-diabetic children. Diabetes Res Clin Pract 71:334–338PubMedCrossRef Nishimura R, Kanda A, Sano H, Matsudaira T, Miyashita Y, Morimoto A, Shirasawa T, Kawaguchi T, Tajima N (2006) Glycated albumin is low in obese, non-diabetic children. Diabetes Res Clin Pract 71:334–338PubMedCrossRef
11.
go back to reference Koga M, Matsumoto S, Saito H, Kasayama S (2006) Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 53:387–391PubMedCrossRef Koga M, Matsumoto S, Saito H, Kasayama S (2006) Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 53:387–391PubMedCrossRef
12.
go back to reference Koga M, Otsuki M, Matsumoto S, Saito H, Mukai M, Kasayama S (2007) Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chim Acta 378:48–52PubMedCrossRef Koga M, Otsuki M, Matsumoto S, Saito H, Mukai M, Kasayama S (2007) Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chim Acta 378:48–52PubMedCrossRef
14.
go back to reference Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144:537–547PubMed Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 144:537–547PubMed
15.
go back to reference Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRef Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979PubMedCrossRef
16.
go back to reference Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321:199–204PubMedCrossRef Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321:199–204PubMedCrossRef
17.
go back to reference Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC (2000) C-reactive protein: relation to total mortality, cardiovascular mortality, and cardiovascular risk factors in men. Eur Heart J 21:1584–1590PubMedCrossRef Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC (2000) C-reactive protein: relation to total mortality, cardiovascular mortality, and cardiovascular risk factors in men. Eur Heart J 21:1584–1590PubMedCrossRef
18.
19.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
20.
go back to reference Schnedl WJ, Lahousen T, Wallner SJ, Krause R, Lipp RW (2005) Silent hemoglobin variants and determination of HbA1c with the high-resolution program of the HPLC HA-8160 haemoglobin analyzer. Clin Biochem 38:88–91PubMedCrossRef Schnedl WJ, Lahousen T, Wallner SJ, Krause R, Lipp RW (2005) Silent hemoglobin variants and determination of HbA1c with the high-resolution program of the HPLC HA-8160 haemoglobin analyzer. Clin Biochem 38:88–91PubMedCrossRef
21.
go back to reference Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S (2002) An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 324:61–71PubMedCrossRef Kouzuma T, Usami T, Yamakoshi M, Takahashi M, Imamura S (2002) An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 324:61–71PubMedCrossRef
22.
go back to reference Kouzuma T, Uemastu Y, Usami T, Imamura S (2004) Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 346:135–143PubMedCrossRef Kouzuma T, Uemastu Y, Usami T, Imamura S (2004) Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 346:135–143PubMedCrossRef
23.
go back to reference Hashimoto K, Kasayama S, Yamamoto H, Kurebayashi S, Kawase I, Koga M (2004) Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, non-smoker subjects without hypertension. Diabet Med 21:581–585PubMedCrossRef Hashimoto K, Kasayama S, Yamamoto H, Kurebayashi S, Kawase I, Koga M (2004) Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, non-smoker subjects without hypertension. Diabet Med 21:581–585PubMedCrossRef
24.
go back to reference Modan M, Meytes D, Rozeman P, Yosef SB, Sehayek E, Yosef NB, Lusky A, Halkin H (1998) Significance of high HbA1 levels in normal glucose tolerance. Diabetes Care 11:422–428CrossRef Modan M, Meytes D, Rozeman P, Yosef SB, Sehayek E, Yosef NB, Lusky A, Halkin H (1998) Significance of high HbA1 levels in normal glucose tolerance. Diabetes Care 11:422–428CrossRef
25.
go back to reference Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, Welch A, Wareham NJ (2001) Cigarette smoking and glycaemia: the EPIC–norfolk study. European prospective investigation into cancer. Int J Epidemiol 30:547–554PubMedCrossRef Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, Welch A, Wareham NJ (2001) Cigarette smoking and glycaemia: the EPIC–norfolk study. European prospective investigation into cancer. Int J Epidemiol 30:547–554PubMedCrossRef
26.
go back to reference Gunton JE, Davies L, Wilmshurst E, Fulcher G, McElduff A (2002) Cigarette smoking affects glycemic control in diabetes. Diabetes Care 25:796–797PubMedCrossRef Gunton JE, Davies L, Wilmshurst E, Fulcher G, McElduff A (2002) Cigarette smoking affects glycemic control in diabetes. Diabetes Care 25:796–797PubMedCrossRef
27.
go back to reference Ko GT, Chan JC, Tsang LW, Critchley JA, Cockram CS (2001) Smoking and diabetes in Chinese men. Postgrad Med J 77:240–243PubMedCrossRef Ko GT, Chan JC, Tsang LW, Critchley JA, Cockram CS (2001) Smoking and diabetes in Chinese men. Postgrad Med J 77:240–243PubMedCrossRef
28.
go back to reference McCulloch P, Lee S, Higgins R, McCall K, Schade DS (2002) Effect of smoking on hemoglobin A1c and body mass index in patients with type 2 diabetes mellitus. J Investig Med 50:284–287PubMedCrossRef McCulloch P, Lee S, Higgins R, McCall K, Schade DS (2002) Effect of smoking on hemoglobin A1c and body mass index in patients with type 2 diabetes mellitus. J Investig Med 50:284–287PubMedCrossRef
29.
go back to reference Bulló M, Garcia-Lorda P, Megias I, Salas-Salvadó J (2003) Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11:525–531PubMedCrossRef Bulló M, Garcia-Lorda P, Megias I, Salas-Salvadó J (2003) Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 11:525–531PubMedCrossRef
30.
go back to reference Don BR, Kaysen G (2004) Serum albumin: relationship to inflammation and nutrition. Semin Dial 17:432–437PubMedCrossRef Don BR, Kaysen G (2004) Serum albumin: relationship to inflammation and nutrition. Semin Dial 17:432–437PubMedCrossRef
Metadata
Title
Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels
Authors
Masafumi Koga
Hiroshi Saito
Mikio Mukai
Michio Otsuki
Soji Kasayama
Publication date
01-06-2009
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 2/2009
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-008-0072-5

Other articles of this Issue 2/2009

Acta Diabetologica 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine